NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis $2.27 -0.01 (-0.44%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.32 +0.05 (+2.20%) As of 05/27/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vivos Therapeutics Stock (NASDAQ:VVOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos Therapeutics alerts:Sign Up Key Stats Today's Range$2.25▼$2.4650-Day Range$2.08▼$3.7152-Week Range$1.91▼$6.28Volume145,533 shsAverage Volume455,858 shsMarket Capitalization$13.37 millionP/E RatioN/ADividend YieldN/APrice Target$4.82Consensus RatingModerate Buy Company OverviewVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Read More… Vivos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreVVOS MarketRank™: Vivos Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 815th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVivos Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Vivos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVivos Therapeutics has a P/B Ratio of 10.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vivos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.65% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently increased by 17.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos Therapeutics does not currently pay a dividend.Dividend GrowthVivos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.65% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently increased by 17.59%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.45 News SentimentVivos Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vivos Therapeutics this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vivos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 26.35% of the stock of Vivos Therapeutics is held by institutions.Read more about Vivos Therapeutics' insider trading history. Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VVOS Stock News HeadlinesVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comEarnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock risesMay 17, 2025 | uk.investing.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 28, 2025 | Premier Gold Co (Ad)Vivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 17, 2025 | finanznachrichten.deVivos Therapeutics Inc (VVOS) Q1 2025 Earnings Call Highlights: Strategic Acquisitions and FDA ...May 17, 2025 | finance.yahoo.comVivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial ChallengesMay 16, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 15, 2025 | finance.yahoo.comSee More Headlines VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed this year? Vivos Therapeutics' stock was trading at $4.29 at the start of the year. Since then, VVOS shares have decreased by 47.1% and is now trading at $2.27. View the best growth stocks for 2025 here. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $3.63 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 335.04% and a negative net margin of 86.19%. Read the conference call transcript. When did Vivos Therapeutics' stock split? Vivos Therapeutics's stock reverse split on the morning of Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Vivos Therapeutics' top institutional shareholders include Cutter & CO Brokerage Inc. (0.83%) and EWA LLC (0.18%). View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vivos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP). Company Calendar Last Earnings5/15/2025Today5/27/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:VVOS CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$4.82 High Stock Price Target$6.20 Low Stock Price Target$2.25 Potential Upside/Downside+112.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.58 million Net Margins-86.19% Pretax Margin-86.19% Return on Equity-335.04% Return on Assets-93.58% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$14.63 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book10.32Miscellaneous Outstanding Shares5,890,000Free Float5,713,000Market Cap$13.37 million OptionableOptionable Beta7.31 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VVOS) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.